Theravance Biopharma (TBPH) Equity Income (2018 - 2022)

Theravance Biopharma (TBPH) has 5 years of Equity Income data on file, last reported at $28.1 million in Q2 2022.

• Equity Income for Q2 2022 came in at $28.1 million, up 28.28% year-over-year; the trailing twelve-month figure through Jun 2022 was $118.8 million (up 64.9% YoY), and the FY2021 annual result was $104.0 million, up 51.94% from the prior year.
• Equity Income improved to $28.1 million in Q2 2022 per TBPH's latest filing, from $25.1 million in the prior quarter.
• Over five years, Equity Income peaked at $35.3 million in Q4 2021 and troughed at $686000.0 in Q1 2018.
• A 5-year average of $15.0 million and a median of $13.5 million in 2020 frame the typical range for Equity Income.
• The sharpest annual moves came in 2019 and 2021: Equity Income surged 808.02% in 2019, then gained 2.55% in 2021.
• A 5-year view of Equity Income shows it stood at $5.4 million in 2018, then soared by 119.47% to $11.9 million in 2019, then jumped by 69.05% to $20.1 million in 2020, then jumped by 75.31% to $35.3 million in 2021, then fell by 20.33% to $28.1 million in 2022.
• Business Quant data shows TBPH's Equity Income at $28.1 million in Q2 2022, $25.1 million in Q1 2022, and $35.3 million in Q4 2021.